---
title: Benzodiazepine (and Barbiturate) Comparison
authors:
  - author: 'Curtis Geier, PharmD'
categories:
  - Pharmacology
  - Toxicology
created: 2019/12/31
updated: ''
---
![Benzodiazepine Barbiturate Comparison Table](/media/Benzodiazepine-Barbiturate-Comparison-Table.png "Benzodiazepine Barbiturate Comparison Table")

## Clinical Implications [2,10]
* All benzodiazepines and barbiturates are **metabolized by the liver**.
  * Chlordiazepoxide, diazepam, midazolam, phenobarbital 
>Phase I metabolism (CYP450 system): prolonged half-lives and durations of effect with hepatic dysfunction.
  * Lorazepam
>Phase II metabolism (glucuronidation): less effect from hepatic dysfunction.

* Benzodiazepines exert their primary action in the central nervous system and drug permeability across the blood brain barrier is enhanced by the lipophilicity of the molecule. *A more lipophilic benzodiazepine will have a quicker onset of action once in systemic circulation. *
  * Diazepam has the fastest onset when administered IV directly into systemic circulation. Lorazepam has a slightly slower onset, and midazolam slower yet when administered IV.

* Lipophilicity also affects the rate of absorption via other routes of administration. A more lipophilic benzodiazepine is more slowly absorbed following intramuscular administration affecting the onset of action.
  * Midazolam has the fastest onset when administered IM, lorazepam is slower, and diazepam is unreliably absorbed following IM administration.

* Finally, lipophilicity also affects the duration of action. A more lipophilic compound quickly permeates the blood brain barrier resulting in rapid onset, it then quickly diffuses out of the CNS and into lipid tissue.
  * Diazepam has a short duration of action with a single dose despite its long T1/2. 
  * With repeated dosing the concentration will accumulate saturating the lipid tissue, and protein binding, and the duration of effect will lengthen to approach the T1/2.

## References
1.	Greenblatt DJ, Arendt RM, Abernethy DR et al. In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. Br J Anaesth. 1983 Oct;55(10):985-9. PMID 6626413
2.	Brunton LL, Knollmann BC, Hilal-Dandan R. Goodman & Gilman's the Pharmacological Basis of Therapeutics. Thirteenth ed. New York: McGraw Hill Medical; 2018.
3.	Greenblatt DJ, Shader RI, Harmatz JS et al. Absorption rate, blood concentrations, and early response to oral chlordiazepoxide. Am J Psychiatry. 1977 May;134(5):559-62. PMID 848586
4.	Greenblatt DJ, Harmatz JS, Friedman H et al. A large-sample study of diazepam pharmacokinetics. Ther Drug Monit. 1989b;11(6):652-657. PMID 2512694
5.	Greenblatt DJ, Divoll M, Harmatz JS et al. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci. 1982;71(2):248-252. PMID 6121043
6.	Gale GD, Galloon S, Porter WR. Sublingual lorazepam: a better premedication? Br J Anaesth. 1983 Aug;55(8):761-5. PMID 6136288
7.	Fresenius Kabi. Midazolam USP [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208878Orig1s000lbl.pdf. Revised [2017].
8.	Pentik채inen PJ, V채lisalmi L, Himberg JJ et al. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol. 1989 Mar;29(3):272-7. PMID 2723115
9.	Phenobarbital Sodium USP [package insert]. Boucherville, QC, Canada: Sandoz Canada Inc.; 2015
10.	Greenblatt DJ, Shader RI, Divoll M et al. Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol. 1981;11 Suppl 1:11S-16S. PMID 61335281.	Greenblatt DJ, Arendt RM, Abernethy DR et al. In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. Br J Anaesth. 1983 Oct;55(10):985-9. PMID 6626413
2.	Brunton LL, Knollmann BC, Hilal-Dandan R. Goodman & Gilman's the Pharmacological Basis of Therapeutics. Thirteenth ed. New York: McGraw Hill Medical; 2018.
3.	Greenblatt DJ, Shader RI, Harmatz JS et al. Absorption rate, blood concentrations, and early response to oral chlordiazepoxide. Am J Psychiatry. 1977 May;134(5):559-62. PMID 848586
4.	Greenblatt DJ, Harmatz JS, Friedman H et al. A large-sample study of diazepam pharmacokinetics. Ther Drug Monit. 1989b;11(6):652-657. PMID 2512694
5.	Greenblatt DJ, Divoll M, Harmatz JS et al. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci. 1982;71(2):248-252. PMID 6121043
6.	Gale GD, Galloon S, Porter WR. Sublingual lorazepam: a better premedication? Br J Anaesth. 1983 Aug;55(8):761-5. PMID 6136288
7.	Fresenius Kabi. Midazolam USP [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208878Orig1s000lbl.pdf. Revised [2017].
8.	Pentik채inen PJ, V채lisalmi L, Himberg JJ et al. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol. 1989 Mar;29(3):272-7. PMID 2723115
9.	Phenobarbital Sodium USP [package insert]. Boucherville, QC, Canada: Sandoz Canada Inc.; 2015
10.	Greenblatt DJ, Shader RI, Divoll M et al. Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol. 1981;11 Suppl 1:11S-16S. PMID 6133528

